Orexin Receptor Antagonism and Sleep in Stimulant Use Disorder

Stimulant Use Disorder Clinical Trial

Official title:
Orexin Receptor Antagonism and Sleep in Stimulant Use Disorder: A Pilot Study

Status Not yet recruiting

Clinical Trial Summary

The purpose of this study is to determine the effects of suvorexant (SUVO), on sleep, stress, and drug craving during early abstinence from stimulants and to determine the effects of treatment (SUVO vs. treatment as usual (TAU)) on post-treatment (Days 13-30) residential program length of stay (LOS) and completion rate.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Stimulant Use Disorder

Clinical Trial Details

NCT number	NCT06444256
Study type	Interventional
Source	The University of Texas Health Science Center, Houston
Contact	Heather Webber, PhD
Phone	713-486-2723
Email	Heather.E.Webber@uth.tmc.edu
Status	Not yet recruiting
Phase	Phase 2
Start date	June 30, 2024
Completion date	June 30, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05286879` - Addressing Risk Through Community Treatment for Infectious Disease and Opioid Use Disorder Now (ACTION) Among Justice-involved Populations	N/A
Active, not recruiting	`NCT05288751` - Contingency Management for Opioid and Stimulant Use Disorders in Primary Care	N/A
Recruiting	`NCT04228276` - Treating Stimulant Addiction With Repetitive Transcranial Magnetic Stimulation	N/A
Active, not recruiting	`NCT04907357` - rTMS for Stimulant Use Disorders	N/A
Recruiting	`NCT05546515` - Suvorexant for Opioid/Stimulant Co-use	Phase 2
Not yet recruiting	`NCT06323837` - Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treatment	Phase 2